The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
 
Nick Pavlakis
Consulting or Advisory Role - Amgen; AstraZeneca; Beigene; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - Bayer (Inst); Pfizer (Inst); Roche (Inst)
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Janssen; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Katrin Marie Sjoquist
Honoraria - BMS; Ipsen; Merck; MSD; SERVIER
Research Funding - Bayer (Inst)
Other Relationship - Novotech
 
Andrew James Martin
No Relationships to Disclose
 
Anthony Jaworski
No Relationships to Disclose
 
Sonia Yip
No Relationships to Disclose
 
Yung-Jue Bang
Consulting or Advisory Role - Alexo Therapeutics; Amgen; Astellas Pharma; Daewoong Pharmaceutical; Hanmi; Samyang
 
Thierry Alcindor
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; BMS; Merck
Research Funding - Astellas Pharma (Inst); Deciphera (Inst); EMD Serono (Inst); Epizyme (Inst); Karyopharm Therapeutics (Inst); SpringWorks Therapeutics (Inst)
 
Christopher J. O'Callaghan
No Relationships to Disclose
 
Niall C. Tebbutt
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Merck; Pierre Fabre
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pierre Fabre
Speakers' Bureau - Eisai
 
Andrew Strickland
No Relationships to Disclose
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Eutilex; Indivumed; LG Chem; MSD Oncology; Sanofi
Speakers' Bureau - Amgen; BMS/Ono; Eisai; Lilly; MSD Oncology
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Lilly; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Keun-Wook Lee
Honoraria - Boryung; JW Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; Sanofi/Aventis; Vifor Pharma
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); Genome & Company (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
John Raymond Zalcberg
Leadership - ICON Group; Lipotek
Stock and Other Ownership Interests - Amarin Corporation; Biomarin; Concert Pharmaceuticals; Frequency Therapeutics; Gilead Sciences; Madrigal Pharmaceuticals; Moderna Therapeutics; Novavax; Opthea; Orphazyme; Twist Bioscience; UniQure; Zogenix
Honoraria - Deciphera; Gilead Sciences; Halozyme; Merck Serono; MSD Oncology; Specialised Therapeutics; Targovax; Viatris
Consulting or Advisory Role - 1Globe Health Institute; Alloplex Biotherapeutics Inc; Center for Emerging & Neglected Diseases (CEND); Deciphera; FivePHusion; Genor BioPharma; Lisata; Merck Sharp & Dohme; NOUS Group; Novotech; Revolution Medicines; Specialised Therapeutics
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Medtronic (Inst); MSD Oncology (Inst); Mylan (Inst); Pfizer (Inst)
 
Timothy Jay Price
Honoraria - SERVIER
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Merck
Research Funding - AMGEN (Inst)
Travel, Accommodations, Expenses - Amgen
 
John Simes
Consulting or Advisory Role - FivePhusion (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
David Goldstein
Honoraria - AstraZeneca; Boehringer Ingelheim; Sun Biopharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Seagen; sun biopharma
Research Funding - Amgen (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); pfizer (Inst); Zucero Therapeutics (Inst)